1887

Abstract

AIDS remains a major global health concern. Despite a number of therapeutic advancements, there is still an urgent need to develop a new class of therapy for human immunodeficiency virus (HIV). Here, it was shown that 1′-1′-acetoxychavicol acetate (ACA), a small molecular compound isolated from the rhizomes of , inhibited Rev transport at a low concentration by binding to chromosomal region maintenance 1 and accumulating full-length HIV-1 RNA in the nucleus, resulting in a block in HIV-1 replication in peripheral blood mononuclear cells. Additionally, ACA and didanosine acted synergistically to inhibit HIV-1 replication. Thus, ACA may represent a novel treatment for HIV-1 infection, especially in combination with other anti-HIV drugs.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.81685-0
2006-07-01
2019-10-17
Loading full text...

Full text loading...

/deliver/fulltext/jgv/87/7/2047.html?itemId=/content/journal/jgv/10.1099/vir.0.81685-0&mimeType=html&fmt=ahah

References

  1. Ando, S., Matsuda, H., Morikawa, T. & Yoshikawa, M. ( 2005; ). 1′S-1′-Acetoxychavicol acetate as a new type inhibitor of interferon-β production in lipopolysaccharide-activated mouse peritoneal macrophages. Bioorg Med Chem 13, 3289–3294.[CrossRef]
    [Google Scholar]
  2. Bevec, D., Dobrovnik, M., Hauber, J. & Böhnlein, E. ( 1992; ). Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator. Proc Natl Acad Sci U S A 89, 9870–9874.[CrossRef]
    [Google Scholar]
  3. Bevec, D., Jaksche, H., Oft, M. & 9 other authors ( 1996; ). Inhibition of HIV-1 replication in lymphocytes by mutants of the Rev cofactor eIF-5A. Science 271, 1858–1860.[CrossRef]
    [Google Scholar]
  4. Biesert, L., Zimmermann, F., Schroder, B., Matthes, E., Suhartono, H., Dietrich, U. & Rubsamen-Waigmann, H. ( 1991; ). Biochemical and genetical analysis of AZT-resistant HIV-mutants. Behring Inst Mitt 89, 74–80.
    [Google Scholar]
  5. De Pooter, H. L., Omar, M. N., Coolsaet, B. A. & Schamp, N. M. ( 1985; ). The essential oil of greater galanga (Alpinia galanga) from Malaysia. Phytochemistry 24, 93–96.[CrossRef]
    [Google Scholar]
  6. Duan, L., Bagasra, O., Laughlin, M. A., Oakes, J. W. & Pomerantz, R. J. ( 1994; ). Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci U S A 91, 5075–5079.[CrossRef]
    [Google Scholar]
  7. Felber, B. K., Hadzopoulou-Cladaras, M., Cladaras, C., Copeland, T. & Pavlakis, G. N. ( 1989; ). rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc Natl Acad Sci U S A 86, 1495–1499.[CrossRef]
    [Google Scholar]
  8. Hadzopoulou-Cladaras, M., Felber, B. K., Cladaras, C., Athanassopoulos, A., Tse, A. & Pavlakis, G. N. ( 1989; ). The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region. J Virol 63, 1265–1274.
    [Google Scholar]
  9. Janssen, A. M. & Scheffer, J. J. C. ( 1985; ). Acetoxyhydroxychavicol acetate, an antifungal component of Alpinia galanga. Planta Med 6, 507–511.
    [Google Scholar]
  10. Kalland, K.-H., Szilvay, A. M., Brokstad, K. A., Sætrevik, W. & Haukenes, G. ( 1994; ). The human immunodeficiency virus type 1 Rev protein shuttles between the cytoplasm and nuclear compartments. Mol Cell Biol 14, 7436–7444.
    [Google Scholar]
  11. Kawabata, K., Tanaka, T., Yamamoto, T. & 7 other authors ( 2000; ). Suppression of N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis by dietary feeding of 1′-acetoxychavicol acetate. Jpn J Cancer Res 91, 148–155.[CrossRef]
    [Google Scholar]
  12. Kobayashi, Y., Nakae, D., Akai, H. & 9 other authors ( 1998; ). Prevention by 1′-acetoxychavicol acetate of the induction but not growth of putative preneoplastic, glutathione S-transferase placental form-positive, focal lesions in the livers of rats fed a choline-deficient, l-amino acid-defined diet. Carcinogenesis 19, 1809–1814.[CrossRef]
    [Google Scholar]
  13. Kudo, N., Wolff, B., Sekimoto, T., Schreiner, E. P., Yoneda, Y., Yanagida, M., Horinouchi, S. & Yoshida, M. ( 1998; ). Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp Cell Res 242, 540–547.[CrossRef]
    [Google Scholar]
  14. Kudo, N., Matsumori, N., Taoka, H., Fujiwara, D., Schreiner, E. P., Wolff, B., Yoshida, M. & Horinouchi, S. ( 1999; ). Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci U S A 96, 9112–9117.[CrossRef]
    [Google Scholar]
  15. Lee, T. C., Sullenger, B. A., Gallardo, H. F., Ungers, G. E. & Gilboa, E. ( 1992; ). Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. New Biol 4, 66–74.
    [Google Scholar]
  16. Malim, M. H., Hauber, J., Le, S.-Y., Maizel, J. V. & Cullen, B. R. ( 1989; ). The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 338, 254–257.[CrossRef]
    [Google Scholar]
  17. Matsuda, H., Morikawa, T., Managi, H. & Yoshikawa, M. ( 2003; ). Antiallergic principles from Alpinia galanga: structural requirements of phenylpropanoids for inhibition of degranulation and release of TNF-α and IL-4 in RBL-2H3 cells. Bioorg Med Chem Lett 13, 3197–3202.[CrossRef]
    [Google Scholar]
  18. Matsukura, M., Zon, G., Shinozuka, K. & 7 other authors ( 1989; ). Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A 86, 4244–4248.[CrossRef]
    [Google Scholar]
  19. Menéndez-Arias, L. ( 2002; ). Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol Sci 23, 381–388.[CrossRef]
    [Google Scholar]
  20. Meyer, B. E. & Malim, M. H. ( 1994; ). The HIV-1 Rev trans-activator shuttles between the nucleus and the cytoplasm. Genes Dev 8, 1538–1547.[CrossRef]
    [Google Scholar]
  21. Miyauchi, M., Nishikawa, A., Furukawa, F., Nakamura, H., Son, H.-Y., Murakami, A., Koshimizu, K., Ohigashi, H. & Hirose, M. ( 2000; ). Inhibitory effects of 1′-acetoxychavicol acetate on N-nitrosobis(2-oxopropyl)-amine-induced initiation of cholangiocarcinogenesis in Syrian hamsters. Jpn J Cancer Res 91, 477–481.[CrossRef]
    [Google Scholar]
  22. Morita, H. & Itokawa, H. ( 1988; ). Cytotoxic and antifungal diterpenes from the seeds of Alpinia galanga. Planta Med 54, 117–120.[CrossRef]
    [Google Scholar]
  23. Murakami, A., Ohura, S., Nakamura, Y., Koshimizu, K. & Ohigashi, H. ( 1996; ). 1′-Acetoxychavicol acetate, a superoxide anion generator inhibitor, potently inhibits tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in ICR mouse skin. Oncology 53, 386–391.[CrossRef]
    [Google Scholar]
  24. Murakami, N., Ye, Y., Kawanishi, M., Aoki, S., Kudo, N., Yoshida, M., Nakayama, E. E., Shioda, T. & Kobayashi, M. ( 2002; ). New Rev-transport inhibitor with anti-HIV activity from Valerianae radix. Bioorg Med Chem Lett 12, 2807–2810.[CrossRef]
    [Google Scholar]
  25. Najera, I., Richman, D. D., Olivares, I., Rojas, J. M., Peinado, M. A., Perucho, M., Najera, R. & López-Galíndez, C. ( 1994; ). Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses 10, 1479–1488.[CrossRef]
    [Google Scholar]
  26. Ohnishi, M., Tanaka, T., Makita, H. & 7 other authors ( 1996; ). Chemopreventive effect of a xanthine oxidase inhibitor, 1′-acetoxychavicol acetate, on rat oral carcinogenesis. Jpn J Cancer Res 87, 349–356.[CrossRef]
    [Google Scholar]
  27. Palittapongarnpim, P., Kirdmanee, C., Kittakoop, P. & Rukseree, K. ( 2002; ). 1′-Acetoxychavicol Acetate for Tuberculosis Treatment. US Patent Application no. 2002192262.
  28. Pani, A., Loi, A. G., Mura, M., Marceddu, T., La Colla, P. & Marongiu, M. E. ( 2002; ). Targeting HIV: old and new players. Curr Drug Targets Infect Disord 2, 17–32.[CrossRef]
    [Google Scholar]
  29. Ratmeyer, L., Zapp, M. L., Green, M. R., Vinayak, R., Kumar, A., Boykin, D. W. & Wilson, W. D. ( 1996; ). Inhibition of HIV-1 Rev-RRE interaction by diphenylfuran derivatives. Biochemistry 35, 13689–13696.[CrossRef]
    [Google Scholar]
  30. St Clair, M. H., Martin, J. L., Tudor-Williams, G., Bach, M. C., Vavro, C. L., King, D. M., Kellam, P., Kemp, S. D. & Larder, B. A. ( 1991; ). Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253, 1557–1559.[CrossRef]
    [Google Scholar]
  31. Tanaka, T., Kawabata, K., Kakumoto, M. & 8 other authors ( 1997a; ). Chemoprevention of azoxymethane-induced rat colon carcinogenesis by a xanthine oxidase inhibitor, 1′-acetoxychavicol acetate. Jpn J Cancer Res 88, 821–830.[CrossRef]
    [Google Scholar]
  32. Tanaka, T., Makita, H., Kawamori, T. & 7 other authors ( 1997b; ). A xanthine oxidase inhibitor 1′-acetoxychavicol acetate inhibits azoxymethane-induced colonic aberrant crypt foci in rats. Carcinogenesis 18, 1113–1118.[CrossRef]
    [Google Scholar]
  33. Tözsér, J. ( 2001; ). HIV inhibitors: problems and reality. Ann N Y Acad Sci 946, 145–159.
    [Google Scholar]
  34. Witvrouw, M., van Maele, B., Vercammen, J., Hantson, A., Engelborghs, Y., de Clercq, E., Pannecouque, C. & Debyser, Z. ( 2004; ). Novel inhibitors of HIV-1 integration. Curr Drug Metab 5, 291–304.[CrossRef]
    [Google Scholar]
  35. Wolff, B., Sanglier, J. J. & Wang, Y. ( 1997; ). Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem Biol 4, 139–147.[CrossRef]
    [Google Scholar]
  36. Yoshikawa, M., Matsuda, H. & Morikawa, T. ( 2004; ). Antiallergy agent obtained from Alpinia galanga and method for production thereof. Jpn Kokai Tokkyo Koho patent no. 2004189669 (in Japanese).
  37. Zapp, M. L., Stern, S. & Green, M. R. ( 1993; ). Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production. Cell 74, 969–978.[CrossRef]
    [Google Scholar]
  38. Zapp, M. L., Young, D. W., Kumar, A., Singh, R., Boykin, D. W., Wilson, W. D. & Green, M. R. ( 1997; ). Modulation of the rev-RRE interaction by aromatic heterocyclic compounds. Bioorg Med Chem 5, 1149–1155.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.81685-0
Loading
/content/journal/jgv/10.1099/vir.0.81685-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error